Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 14, 2022; 28(22): 2437-2456
Published online Jun 14, 2022. doi: 10.3748/wjg.v28.i22.2437
Published online Jun 14, 2022. doi: 10.3748/wjg.v28.i22.2437
Figure 11 Validation of proteomics results using Western blot analysis of MRPL35, TP53, BCL2L1, COPS5, BAX, and BAD in cells treated with different concentrations of 18β-glycyrrhetinic acid for 48 h.
β-tubulin was used as the loading control. A: MRPL35; B: TP53; C: BCL2L1; D: COPS5; E: BAX; F: BAD n = 4, aP < 0.05; bP < 0.01; cP < 0.001. 18β-GRA: 18β-glycyrrhetinic acid; MRPL35: Mitochondrial Ribosomal Protein L35.
- Citation: Yuan L, Yang Y, Li X, Zhou X, Du YH, Liu WJ, Zhang L, Yu L, Ma TT, Li JX, Chen Y, Nan Y. 18β-glycyrrhetinic acid regulates mitochondrial ribosomal protein L35-associated apoptosis signaling pathways to inhibit proliferation of gastric carcinoma cells. World J Gastroenterol 2022; 28(22): 2437-2456
- URL: https://www.wjgnet.com/1007-9327/full/v28/i22/2437.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i22.2437